Zoetis (FRA:ZOE) Net Income From Continuing Operations : €2,171 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Zoetis Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Zoetis's net income from continuing operations for the three months ended in Dec. 2023 was €480 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was €2,171 Mil.

Zoetis Net Income From Continuing Operations Historical Data

The historical data trend for Zoetis's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zoetis Net Income From Continuing Operations Chart

Zoetis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

1,350.00

1,344.79

1,800.09

1,992.78

2,145.78

Zoetis Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial															434.24	514.63	618.41	558.45	479.59

Zoetis Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €2,171 Mil.

Zoetis (FRA:ZOE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zoetis Inc (FRA:ZOE) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

ZTS:USA ZTS:Mexico 1ZTS:Italy ZOE:Germany ZOE:Germany Z1TS34:Brazil

Address

10 Sylvan Way, Parsippany, NJ, USA, 07054

Website

https://www.zoetis.com

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Zoetis (FRA:ZOE) Headlines

No Headlines